These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
    Author: Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A.
    Journal: Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536.
    Abstract:
    BACKGROUND: HBME-1 has been recognized as a useful marker for diagnosing thyroid carcinoma. In this study, we investigated whether it has a diagnostic value for discriminating follicular carcinoma from adenoma. MATERIALS AND METHODS: We investigated HBME-1 expression in 138 follicular carcinomas, 155 follicular adenomas, 98 adenomatous nodules and 37 papillary carcinomas, using anti-HBME-1 monoclonal antibody. RESULTS: HBME-1 was positive in 60.9% of follicular carcinoma and the incidence was significantly higher (p<0.0001) than that of follicular adenoma, 30.3%. In adenomatous nodules, only 17.3% were classified as positive, which was lower even than that of follicular adenoma (p=0.0257). All papillary carcinomas examined were positive for HBME-1. We calculated the positive predictive value of HBME-1 in discriminating follicular carcinoma from adenoma as 64.2%. CONCLUSION: These results suggest that, although HBME-1 contributes to the diagnosis of papillary carcinoma, it could not be applied in the preoperative diagnosis of follicular carcinoma, for example, using fine-needle aspiration biopsy samples.
    [Abstract] [Full Text] [Related] [New Search]